Trial Condition(s):

Carcinoma, Renal Cell

Nexavar post-marketing surveillance for renal cell carcinoma in Japan

Bayer Identifier:

15038

ClinicalTrials.gov Identifier:

NCT01411423

EudraCT Number:

Not Available

Study Completed

Trial Purpose

This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have been administered with Nexavar for unresectable or advanced renal cell carcinoma (RCC). The objective of this study is to assess safety and effectiveness of Nexavar under real-life practice conditions. This study is an all case investigation of which the enrollment period is 15 months, and all patients who received Nexavar will be recruited and followed one year since starting Nexavar administration.

Inclusion Criteria
- Patients who received Nexavar for unresectable or advanced renal cell carcinoma
Exclusion Criteria
- Patients who are contraindicated based on the product label

Trial Summary

Enrollment Goal
3305
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Nexavar (Sorafenib, BAY43-9006)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Japan

Status
Completed
 

Trial Design